NeuroDerm Announces Positive Results Of A Phase II Study Of ND0611 Dermal Patch In Patients With Parkinson's Disease

NeuroDerm, Ltd. announced today the results of a Phase I/II safety and pharmacokinetic trial of ND0611, administered as an adjunct therapy to Sinemet�, Sinemet� CR or Stalevo�, in patients with advanced Parkinson's disease. ND0611 is a proprietary carbidopa liquid formula administered sub-cutaneously via a dermal patch to increase the bioavailability and efficacy of orally- administered levodopa. Results of this study support the continued development of ND0611 for the treatment of Parkinson's disease...

dr oz